Compass Therapeutics, Inc.
$5.42
▲
0.37%
2026-04-21 06:06:02
www.compasstherapeutics.com
NCM: CMPX
Explore Compass Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.08 B
Current Price
$5.42
52W High / Low
$6.88 / $1.6
Stock P/E
—
Book Value
$1.1
Dividend Yield
—
ROCE
-35.42%
ROE
-41.29%
Face Value
—
EPS
$-0.42
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
39
Beta
1.3
Debt / Equity
5
Current Ratio
15.02
Quick Ratio
15.02
Forward P/E
-10.72
Price / Sales
—
Enterprise Value
$731.98 M
EV / EBITDA
-10.09
EV / Revenue
—
Rating
Strong Buy
Target Price
$13.64
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Arcellx, Inc. | $115 | — | $6.73 B | — | -50.64% | -53.42% | $115.13 / $47.86 | $6.95 |
| 2. | BridgeBio Pharma, Inc. | $74.02 | — | $14.41 B | — | -77.47% | 40.79% | $84.94 / $31.77 | $-10.71 |
| 3. | Dianthus Therapeutics, Inc. | $91.92 | — | $5 B | — | -35.57% | -38.38% | $96.5 / $16.64 | $11.41 |
| 4. | Actinium Pharmaceuticals, Inc. | $1.44 | — | $42.98 M | — | -82.74% | -1.67% | $1.95 / $0.95 | $0.25 |
| 5. | Allogene Therapeutics, Inc. | $2.42 | — | $582.63 M | — | -53.97% | -53.42% | $4.46 / $0.86 | $1.27 |
| 6. | Mirum Pharmaceuticals, Inc. | $95.71 | — | $5.78 B | — | -3.47% | -8.65% | $109.28 / $38.22 | $6.06 |
| 7. | Whitehawk Therapeutics, Inc. | $4.23 | — | $193.98 M | — | -83.93% | -21.82% | $4.48 / $1.39 | $2.89 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -17.99 M | -15.82 M | -21.07 M | -17.97 M | -16.57 M | — |
| Net Profit | -15.72 M | -14.26 M | -19.88 M | -16.63 M | -15.03 M | — |
| EPS in Rs | -0.09 | -0.08 | -0.11 | -0.09 | -0.08 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0.85 M | 0 M | 0 M |
| Operating Profit | -72.84 M | -56.62 M | -50.36 M | -41.66 M |
| Net Profit | -66.49 M | -49.38 M | -42.49 M | -39.23 M |
| EPS in Rs | -0.37 | -0.27 | -0.24 | -0.22 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 219.59 M | 140.4 M | 156.88 M | 199.65 M |
| Total Liabilities | 22.8 M | 15.17 M | 8.34 M | 18.01 M |
| Equity | 196.79 M | 125.23 M | 148.54 M | 181.64 M |
| Current Assets | 209.82 M | 132.75 M | 153.88 M | 194.79 M |
| Current Liabilities | 13.97 M | 8.87 M | 7.8 M | 16.17 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -49.14 M | -44.85 M | -40.62 M | -34.12 M |
| Investing CF | -93.31 M | 46.77 M | 26.96 M | -151.2 M |
| Financing CF | 129.61 M | 17.34 M | 2.94 M | 75.76 M |
| Free CF | -49.17 M | -44.9 M | -40.65 M | -34.34 M |
| Capex | -0.03 M | -0.04 M | -0.03 M | -0.21 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -16.19% | -8.33% | — | — |
| Profit Margin % | -5808.82% | — | — | — |
| Operating Margin % | -6661.76% | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -6455.53% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.